GlobeNewswire

Patient Entrepreneur Finalists Announced for the 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award

Dela

The Summit & Award recognizes and empowers international Patient Entrepreneurs with big ideas that disrupt the future of diabetes management

NEW YORK, Oct. 10, 2017 (GLOBE NEWSWIRE) -- The finalists for the 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award have been announced today.   

The Summit and Award spotlights outstanding Patient Entrepreneurs' innovative efforts and ideas to better manage Diabetes via consumer products, medical devices, or healthcare information technology. At the Summit, the selected Patient Entrepreneurs will have the opportunity to engage with Lyfebulb founders, Novo Nordisk Device R&D leadership, researchers and engineers, as well as venture capitalists. The finalists will participate in a three day, interactive program, which will conclude with the announcement of the three winners, who will receive monetary prizes.

Thanks to the high quality and quantity of applications this year, we have decided to invite 12 finalists instead of 10. They are: Aaron Horowitz of Sproutel, Amin Zayani of Med Angel BV, Charles O'Connell of FitScript LLC, David Weingard of Fit4D, Jeff Dachis of One Drop, Jen Horonjeff of Savvy Cooperative, Josh Wulf of Magikcraft, Laurent Nicolas of DIABNEXT, Linh Le of Bonbouton, Liz Sacco of Diabetes Dabs, Luka Zupancic of Easycarb, and Matthew Loper of Wellth. For more information please visit Lyfebulb's website.

The finalists have been selected from close to 100 applications representing 25 countries around the world, by Lyfebulb founders and senior device researchers from Novo Nordisk. The finalists will attend the Lyfebulb-Novo Nordisk Innovation Summit November 6-8, 2017 hosted by Novo Nordisk A/S in Copenhagen, Denmark. The Summit provides a unique opportunity for visibility and recognition in this highly competitive arena. The winner, as well as the second and third place runners-up, will be chosen by an international judging panel, on November 8, 2017, and awarded monetary prizes in the amounts of $25,000 USD, $15,000 USD, and $10,000 USD, respectively.

"We are thrilled to team up with Novo Nordisk a second year in a row for the 2017 Lyfebulb-Novo Nordisk Innovation Summit and Award, and were impressed by the applications we received from all over the world yet again this year. It was definitely tough to narrow down the large number of quality applications to just twelve, but we are certain that this group of finalists will make this year's event as successful, or an even greater success than last year's Summit," says Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. "Patient entrepreneurs are individuals who have utilized their diagnosis, or that of someone close to the innovator, a relative or loved one, as motivation to form businesses aimed at improving the quality of life of those living with a chronic illness, and are an essential part of the future for people living with chronic disease."

Senior Vice President for Novo Nordisk Device R&D Kenneth Strømdahl adds: "Digital technologies and patient entrepreneurs are fast-tracking towards a transformed future in the device space. I can't wait to meet the twelve finalists and share perspective on what rally all of us around a common goal: dreaming of a better future for patients with diabetes."

More information on the selection process, the Summit, and the finalists can be found here.

About Lyfebulb
Lyfebulb is a business focused on bridging patient communities with industry, and providing a strong voice to people living with chronic disease by empowering patient entrepreneurs and patient ambassadors. See  www.lyfebulb.com Facebook Twitter Instagram Karin Hehenberger LinkedIn , and  Lyfebulb LinkedIn .

About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries. For more information, visit  novonordisk.com , Facebook Twitter LinkedIn YouTube


Further information

Media Novo Nordisk:            
Adam Pittard     +45 3075 5056     agep@novonordisk.com
Ken Inchausti (US)     +1 609 786 8316     kiau@novonordisk.com
             
Media Lyfebulb            
Karin Hehenberger     +1 917 575 0210     karin@lyfebulb.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Lyfebulb via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement15.10.2018 13:25Pressmeddelande

STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health. Palette Life Sciences (former Pharmanest) has announced a licensing agreement with Nestlé Skin Health. The agreement gives Palette Life Sciences the worldwide commercialization and development rights for three products: Deflux®, Solesta® and BarrigelTM. The products are all based on the NASHATM (Non Animal Stabilized Hyaluronic Acid) technology. Palette Life Sciences will focus immediately on sales of Deflux and Solesta and will begin preparing for worldwide commercialization of Barrigel. Nestlé Skin Health will continue to manufacture the products on behalf of Palette Life Sciences. Palette Life Science will continue the development of SHACT under the name LidbreeTM. Lidbree will be submitted for European regulatory review later this year. Karolinska Development is a passive investo

Karolinska Development's portfolio company Pharmanest changes name and signs licensing agreement15.10.2018 13:25Pressmeddelande

STOCKHOLM, October 15, 2018. Karolinska Development's portfolio company Phamanest changes its name to Palette Life Sciences. The company also announces a global licensing agreement with Nestlé Skin Health. Palette Life Sciences (former Pharmanest) has announced a licensing agreement with Nestlé Skin Health. The agreement gives Palette Life Sciences the worldwide commercialization and development rights for three products: Deflux®, Solesta® and BarrigelTM. The products are all based on the NASHATM (Non Animal Stabilized Hyaluronic Acid) technology. Palette Life Sciences will focus immediately on sales of Deflux and Solesta and will begin preparing for worldwide commercialization of Barrigel. Nestlé Skin Health will continue to manufacture the products on behalf of Palette Life Sciences. Palette Life Science will continue the development of SHACT under the name LidbreeTM. Lidbree will be submitted for European regulatory review later this year. Karolinska Development is a passive investo

ICONOVO TECKNAR AVTAL MED MCMASTER UNIVERSITY AVSEENDE UTVECKLING AV VACCIN MOT TUBERKULOS15.10.2018 09:00Pressmeddelande

Det innovativa, Lundabaserade medicinteknikföretaget Iconovo AB (publ) meddelar i dag att bolaget har skrivit samarbetsavtal med McMaster University i Kanada. Avtalet avser utveckling av en torrpulverberedning av inhalerbart vaccin mot tuberkulos som ska användas i Iconovos unika engångsinhalator ICOone. Iconovo kommer att ingå i ett tvärvetenskapligt forsknings- och utvecklingsprojekt som syftar till att ta fram nästa generations virusbaserade vaccin i pulverform som är stabilt i rumstemperatur. Att kunna transportera vaccin utan krav på kylförvaring är en förutsättning för att snabbt och effektivt nå ut till de behövande. I det projekt som nu påbörjas kommer Iconovos unika engångsinhalator ICOone att användas som testplattform för att underlätta en framtida kommersialisering och storskalig tillverkning. Projektet beräknas pågå i tre år och finansieras bland annat av den kanadensiska staten (CIHR/NSERC). Tuberkulos förekommer i hela världen och är en av de tio vanligaste dödsorsakerna

Stillfront Group AB: Babil Games lanserar Arab Gamers' League4.10.2018 10:02Pressmeddelande

PRESSMEDDELANDE 4 oktober 2018 Babil Games, en del av Stillfront Group, ökar affärstillväxten och lanserar Arab Gamers' League, AGL Babil Games, ett dotterbolag till Stillfront Group, inleder partnerskap med kreativa byrån Grape Creations i Dubai och lanserar Arab Gamers' League (AGL), en ny studio som fokuserar på att lansera så kallade 'social casual games' till MENA-regionen. Babil Games kontrollerar 51% av AGL och Grape Creations övriga 49%. Babil Games är ansvarig för verksamheten och sourcing av spel medan Grape Creations ansvarar för marknadsföring och distribution. "Vi är mycket glada över vårt inledda partnerskap med Grape Creations gällande lanseringen av Arab Gamers' League. AGLs fokus är att lansera nästa generations 'social casual games' till MENA-regionen", säger MJ Fahmi, VD för Babil Games. Babil Games kommer att fortsätta att fokusera på MMO-strategispel. Antalet anställda i Babil Games har fördubblats under det senaste året och studion kommer att flytta till ett nytt

Stillfront Group AB: Babil Games launches Arab Gamers' League4.10.2018 10:02Pressmeddelande

PRESS RELEASE 4 October 2018 Babil Games, part of the Stillfront Group, accelerates business growth and launches Arab Gamers' League, AGL Babil Games, a subsidiary of Stillfront Group, is partnering with Dubai based creative agency Grape Creations to launch Arab Gamers' League (AGL), a new studio focused on bringing social casual games to the MENA-region. Babil Games controls 51% of AGL and Grape Creations the other 49%. Babil Games is head of the operations and the sourcing of the games while Grape Creations is responsible for marketing and distribution. "We are pleased to have Grape Creations as our partner for the launch of Arab Gamers League. In AGL we will focus on bringing the next generation of social casual games to the MENA region", says MJ Fahmi, CEO of Babil Games. Babil Games will continue to focus on strategy MMO games. The number of employees in Babil Games has doubled during the year and the studio will relocate to a new larger office in Amman, Jordan. "The expansion is

Hoylu AB: UNITED STATES AIR FORCE SELECTS HOYLU FOR COLLABORATION AND INNOVATION SOLUTIONS28.9.2018 08:30Pressmeddelande

Malmo, Sweden, September 28, 2018 - Hoylu, a leading enterprise collaboration company announced today that the United States Air Force has selected Hoylu Software and multiple large format HoyluWall systems as a digital workspace tool for workspace innovation and collaboration. Hoylu software will be used at multiple sites to create joined environments within the division. The order will be delivered in Q4 2018 and represents a deal value of SEK 3,670,000 in product and software revenue. The Air Force will use the system for training and education purposes, with the ability to connect users together and collaborate in real-time. The order represents a growing market for Hoylu software and services within the government sector. It is expected that Hoylu's solutions will continue to expand within this industry as innovative collaboration solutions are in demand. Hoylu's solutions and software offer new and exciting ways to learn and collaborate smarter, faster and more efficiently. Creat

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum